Clinical trials
ER+ Breast Cancer clinical trials
Below are recruiting er+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 561 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06649331RecruitingPhase 2
Re-trying antibody-drug conjugates for advanced breast cancer
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06665178RecruitingPhase 2
Testing SG after T-DXd in ER+/HER2-low metastatic breast cancer
This trial tests whether a different chemotherapy drug, called sacituzumab govitecan (SG), can help people with ER+/HER2-low metastatic breast cancer who have already been treated with trastuzumab deruxtecan (T-DXd). It also looks at genetic markers in your tumor to predict who might benefit from SG.
Vancouver, British ColumbiaAges 18 years+ - NCT06677944RecruitingPhase 2
Radiation before surgery for early-stage breast cancer
This trial tests giving radiation to the tumor area before surgery for women with early-stage, hormone-sensitive breast cancer. The idea is to see if giving radiation first can help protect healthy tissue while still being effective.
SeoulAges 45 years+ - NCT06678048RecruitingPhase 2
Arsenous acid for hard-to-treat triple-negative breast cancer
This trial tests a medicine called arsenous acid for people with triple-negative breast cancer that has not responded to at least two prior treatments. If you join, you will get arsenous acid plus one of four chemotherapy drugs to see if the combination can shrink tumors.
Guangzhou, GuangdongAges 18–75 - NCT06678269RecruitingPhase 1
Abemaciclib and radiation for metastatic breast cancer
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
Basking Ridge, New JerseyAges 18 years+ - NCT06681064Recruiting
Tracking breast cancer changes during pre-surgery treatment
This study looks at how breast cancer changes while you are receiving chemotherapy or targeted therapy before surgery. The goal is to better understand which treatments work best for different types of breast cancer.
LondonAges 18 years+ - NCT06718010Recruiting
Blood markers and breast cancer treatment results
This study looks at how age-related changes in your blood might affect how well your breast cancer treatment works. It includes people with hormone receptor-positive, HER2-negative breast cancer that has not spread to distant organs.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06744465Recruiting
Light-based monitoring for breast cancer during chemo
This study uses a special light-based device to monitor breast cancer during chemotherapy before surgery. It is for women with HER2-positive or triple-negative breast cancer who are planning chemotherapy first.
Indianapolis, IndianaAges 18 years+ - NCT06768931RecruitingPhase 2
Combination therapy before surgery for triple-negative breast cancer
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Lanzhou, GansuAges 18 years+ - NCT06781762Recruiting
Breast cancer hormone therapy and its effects on heart and brain
This study looks at how starting a common hormone therapy for breast cancer (aromatase inhibitors) affects your heart and brain health over the short term. It compares women starting this treatment to healthy women who are not on the therapy.
Toronto, OntarioAges Any age - NCT06781996RecruitingPhase 3
Digital tool to help manage hormone therapy side effects
This trial tests a digital tool (a smartphone app) to help women and men with early breast cancer manage side effects from hormone therapy. The goal is to improve quality of life during treatment.
VillejuifAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Sarasota, FloridaAges 18 years+ - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT06826885Recruiting
Comparing two types of radiation for breast cancer
This trial is testing how well two different radiation techniques, IMPT and IMRT, work for treating breast cancer. It aims to see which one is safer and more effective, so you might benefit from a potentially better treatment approach.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06833502RecruitingPhase 2
Screening for breast cancer spread after chemo and surgery
This trial aims to find out if doing special scans to check for breast cancer spread to organs (not just lymph nodes) is helpful in certain patients. The study looks at people with breast cancer that had already spread to lymph nodes and did not completely go away with chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT06867484Recruiting
Breast re-irradiation after second lumpectomy
This trial tests whether giving a second round of radiation to the breast after a lumpectomy for a recurrence is safe and effective. It is for people with a specific type of breast cancer (ER+HER2-) who meet strict criteria regarding prior radiation and tumor characteristics.
Boca Raton, FloridaAges 40 years+ - NCT06889688RecruitingPhase 3
New drug combo vs. chemo for advanced triple-negative breast cancer
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06891651Recruiting
21-gene testing for older breast cancer patients with lymph node spread
This trial looks at using a 21-gene test to guide treatment decisions for women aged 65 or older who have breast cancer that has spread to lymph nodes. It aims to see if this test can help avoid unnecessary chemotherapy in this group.
Jinan, ShandongAges 65 years+ - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Los Angeles, CaliforniaAges 18 years+ - NCT06897488RecruitingPhase 2
Omitting endocrine therapy and radiation in low-risk breast cancer
This trial tests whether older women with very low-risk, hormone-positive breast cancer can safely skip endocrine therapy (hormone-blocking pills) and radiation after lumpectomy. It aims to maintain quality of life while keeping cancer from coming back.
Houston, TexasAges 60 years+ - NCT06931769Recruiting
Optimizing treatment for stage III triple-negative breast cancer
This trial studies the best ways to give chemotherapy before and after surgery for stage III triple-negative breast cancer. It aims to improve treatment outcomes by using a personalized approach and patient-reported data.
Enschede, OverijsselAges 18 years+ - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06959537RecruitingPhase 1
Combination drug therapy for triple negative breast cancer
This trial tests a new combination of three drugs (cyclophosphamide, axatilimab, and retifanlimab) for people with metastatic triple negative breast cancer. The goal is to see if adding a low dose of chemotherapy can make the immunotherapy work better.
Houston, TexasAges 18 years+ - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Daphne, AlabamaAges 18 years+
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er+ breast cancer?
- Yes. Clin2 currently lists 561 recruiting er+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.